Bio Platforms

AI-based new drug development ecosystem

SCL Science - KAIST Institute of Translational Research and
Innovative new drug development

Bio Platforms
SCL Science - KAIST Institution for Translational Research
  • Drug candidate discovery

    Time-saver

    Discovery of drug candidate Drug candidate discovery

  • Selection and Validity assessment

  • Clinical trials phase 1-3

    Cost-saver

    Optimization of clinical trial conditions and Simulating potential outcomes

  • New drug approval

Institute of Translational Research

SCL Science - KAIST Institute of Translational Research

  • Prof. Jung Kyoon Choi

    Principal Investigator

    • Department of Bio and Brain Engineering, KAIST
    • SCL Science Outside Director
    • Author of the book 'Gene-Dominated Society'
    • Research areas: Omics, Genomics/Epigenomics, Systems Genetics
  • Prof. Pilnam Kim

    • Department of Bio and Brain Engineering, KAIST
    • Research areas: biomimetic engineering, tissue engineering, biomorphogenesis, biomechanical biology
  • Prof. Jong-eun Park

    • KAIST Graduate School of Medical Science and Engineering
    • Research areas: Single-cell genomics, bioinformatics, cell biology

AI New Drug Development Consulting

Drug Development Support

We provide strategic support throughout the new drug development process.

  • Patient stratification strategy

  • Expanding targets and indications

  • CDx biomarker discovery

AI drug candidate discovery

Accelerating Drug Development Timeline

Innovatively shortens the new drug development time.

  • Platform-based drug candidate discovery

  • Licensing out new drug materials

AI diagnostic algorithm development

Early Disease Detection

Beyond accurate diagnosis, we enable disease prediction and early detection.

  • Disease outbreak risk prediction

Create your future digital healthcare With SCL Science